OccuRx is a company developing therapies for the treatment of ocular inflammation and fibrosis. It leverages its proprietary small molecule drugs to address the unmet clinical need for more targeted ocular therapies to enhance visual acuity and prevent vision loss in inflammatory and degenerative eye disease. The company offers OCX063, a small molecule drug with the potential to prevent the growth of new and abnormal blood vessels and reduce inflammation of the neurons in the retina.